These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38795973)

  • 1. Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction.
    Vergaro G; Del Franco A; Carecci A; Ferrari Chen YF; Aimo A; Forini F; Nicolini G; Kusmic C; Faita F; Castiglione V; De Tata V; Pucci A; Musetti V; Burchielli S; Passino C; Emdin M
    Int J Cardiol; 2024 Aug; 409():132203. PubMed ID: 38795973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure.
    Nishihara Y; Nishimori M; Sawa T; Uemura K; Nagai S; Todo S; Oota E; Odajima S; Takeuchi K; Ichikawa Y; Kintsu M; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Shimizu M; Hirata KI; Tanaka H
    Heart Vessels; 2024 Feb; 39(2):95-104. PubMed ID: 37733071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    De Vecchis R; Paccone A; Di Maio M
    Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sacubitril/valsartan attenuates left ventricular remodeling and improve cardiac function by upregulating apelin/APJ pathway in rats with heart failure].
    Liu HZ; Gao CY; Yuan F; Xu Y; Tian H; Wang SQ; Zhang PF; Shi YN; Wei JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):690-697. PubMed ID: 35856226
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
    Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
    Li X; Braza J; Mende U; Choudhary G; Zhang P
    Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
    Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
    Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
    J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sacubitril-valsartan on aging-related cardiac dysfunction.
    Telesca M; De Angelis A; Donniacuo M; Bellocchio G; Riemma MA; Mele E; Canonico F; Cianflone E; Torella D; D'Amario D; Patti G; Liantonio A; Imbrici P; De Luca A; Castaldo G; Rossi F; Cappetta D; Urbanek K; Berrino L
    Eur J Pharmacol; 2024 Sep; 978():176794. PubMed ID: 38968980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
    Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
    ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
    Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
    Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples.
    Carluccio E; Dini FL; Correale M; Dattilo G; Ciccarelli M; Vannuccini F; Sforna S; Pacileo G; Masarone D; Scelsi L; Ghio S; Tocchetti CG; Mercurio V; Brunetti ND; Nodari S; Ambrosio G; Palazzuoli A;
    Clin Res Cardiol; 2024 Jun; 113(6):856-865. PubMed ID: 37733084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
    Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
    Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
    Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
    Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.